FILTER
LATEST INTERVIEWS
Gareth Clifton
GENERAL MANAGER MOZAMBIQUE, KENMARE RESOURCES
Kenmare discusses its operations in Mozambique and the challenges currently facing the country.
Errol Smart
MD AND CEO, ORION MINERALS
Orion Minerals will be South Africa’s next copper and zinc producer with the Prieska project being a copper-predominant project. Full development is scheduled to begin in early 2020.
Nataliya Katsnelson
DIRECTOR – BUSINESS DEVELOPMENT, GLOBAL CLINICAL TRIALS
GCT is a CRO providing clinical development services for drugs and medical devices, with operations focused on Central and Eastern Europe, Russia and India.
Sam Taylor
PRESIDENT, THE NORTH CAROLINA BIOSCIENCES ORGANIZATION (NCBIO)
NCBIO is dedicated to promoting the future growth and development of North Carolina’s bioscience industry.
Mike Hendriks
COO, AURIS MINERALS
Auris Minerals is an ASX-listed mineral explorer with a strategic land holding in the Bryah Basin in Western Australia.
Roger Dixon
CORPORATE CONSULTANT, SRK CONSULTING
SRK’s team in South Africa sees increased opportunity in environmental and social governance issues.
Anglo American Quellaveco
CEO, ANGLO AMERICAN QUELLAVECO
Anglo American prepares to ramp up its Quellaveco copper project in Peru.
Cathy Zhai
CEO, MONUMENT MINING
Monument Mining is Canadian company that aspires to become a mid-tier gold producer.
Olivier Duterme
REGIONAL DIRECTOR, BANQUE COMMERCIALE DU CONGO (BCDC)
BCDC has existed as a leading domestic bank for 110 years in the Democratic Republic of Congo.
Michelle Carey
GENERAL MANAGER FOR PRODUCT DEVELOPMENT, IMDEX
IMDEX is a global mining technology company that provides solutions to simplify the process of identifying and extracting what is below the earth’s surface.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
